A Phase I-II Study of Dasatinib in Combination With Weekly Paclitaxel for Patients With Metastatic Breast Carcinoma.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Dasatinib (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Jan 2018 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
- 19 Jan 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
- 10 Jun 2017 Biomarkers information updated